Key Corporate Developments:

SEER TECH (06106): Its Hong Kong public offering received 5,934.56 times subscription, with net proceeds from the global offering amounting to approximately HK$995.4 million.

MICOT PHARMA-B (02335): Its Hong Kong public offering was oversubscribed by 1,181.46 times, with the final offer price set at HK$18.2 per share.

An affiliate of ABBISKO-B (02256), Abbisko Pharmaceuticals, has deepened its research collaboration with Eli Lilly to jointly advance a novel candidate drug with global potential.

GUSHENGTANG (02273)'s subsidiary has acquired 100% equity in SANTE CLINICS and SANTE TCM, as well as 90% equity in Tianjin Bainian Renyitang.

AB&B BIO-TECH-B (02627): Its mRNA monkeypox vaccine has received an Investigational New Drug application approval from the Center for Drug Evaluation in China.

Operating Performance:

CATHAY PAC AIR (00293) reported a 17% year-on-year increase in passenger numbers for May, alongside an 11% rise in cargo volume.